Samsung Biologics to showcase global expansion and strategic initiatives at DCAT Week 2026
Samsung Biologics is participating in DCAT Week 2026 in New York City, as part of its ongoing engagement with the global pharmaceutical community.
On the first day of the event, Kevin Sharp, Executive Vice President and Head of Sales and Operations, presented at the DCAT Member Company Announcement Forum, where he shared updates on the company’s continuous capacity and geographical expansion.
During the session, Kevin highlighted Samsung Biologics’ ongoing investments, including the development of Bio Campus III and the planned acquisition of the company’s first U.S. manufacturing site in Rockville, Maryland. He also introduced key strategic initiatives, including the company’s collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to support outbreak-ready vaccine manufacturing, and the establishment of an open innovation center with Eli Lilly, designed to support emerging biotech companies.
Throughout the DCAT Week, Samsung Biologics’ leadership will engage with existing and potential clients at the InterContinental New York Barclay, to discuss how to best support their programs with its manufacturing and development capabilities.
Samsung Biologics is participating in DCAT Week 2026 in New York City, as part of its ongoing engagement with the global pharmaceutical community.
On the first day of the event, Kevin Sharp, Executive Vice President and Head of Sales and Operations, presented at the DCAT Member Company Announcement Forum, where he shared updates on the company’s continuous capacity and geographical expansion.
During the session, Kevin highlighted Samsung Biologics’ ongoing investments, including the development of Bio Campus III and the planned acquisition of the company’s first U.S. manufacturing site in Rockville, Maryland. He also introduced key strategic initiatives, including the company’s collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to support outbreak-ready vaccine manufacturing, and the establishment of an open innovation center with Eli Lilly, designed to support emerging biotech companies.
Throughout the DCAT Week, Samsung Biologics’ leadership will engage with existing and potential clients at the InterContinental New York Barclay, to discuss how to best support their programs with its manufacturing and development capabilities.
Share article
Related Content